On June 27, 2025, Inhibikase Therapeutics held its Annual Meeting where shareholders elected Amit Munshi and David Canner, Ph.D. as directors until 2028, ratified CohnReznick LLP as the accounting firm for 2025, and approved an amendment to the equity incentive plan; with total votes for directors being 56.8 million and 57.7 million respectively.